FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data demonstrating the potentially disease-modifying effects of Lucid-MS, its lead drug candidate for the potential treatment of multiple sclerosis in the animal models of MS. According to the update, InvestmentPitch.com has produced a video discussing the news. Based on over a decade of research, Lucid-MS is a patented neuroprotective new chemical entity that affects protein citrullination and myelin structure, which are associated with the severity of MS lesions. FSD Pharma has released a video explaining its preclinical results in order to demonstrate the unique potential therapeutic value of Lucid-MS. As shown in the video, the subject mouse treated with Lucid-MS demonstrated an improvement in clinical score when compared with the mouse that received the placebo, with the subject showing clinical signs similar to those in a healthy mouse by the end of the study.
In addition, FSD Pharma has announced that Anthony Durkacz, the company’s interim CEO, will present at the H.C. Wainwright 2nd Annual Virtual Psychedelics Conference to be held on Dec. 6, 2021. Durkacz’s presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET on the day of the event, as well as accessible to view on the investor relations section of FSD’s website. Members of FSD Pharma’s management team will also be available for one-on-one investor meetings during the conference.
To view the full press releases, visit https://ibn.fm/zfux5 and https://ibn.fm/hZDWA
About FSD Pharma Inc.
FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc. is focused on pharmaceutical research and development of its lead compound, ultra-micronized palmitoyl ethylamine (“PEA”) or FSD-PEA (formerly called FSD-201). Through its wholly owned subsidiary, Lucid, the company is also focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. For more information, visit the company’s website at www.FSDPharma.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.